<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32770807</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1440-1754</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>56</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of paediatrics and child health</Title>
          <ISOAbbreviation>J Paediatr Child Health</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Kawasaki disease fact check: Myths, misconceptions and mysteries.</ArticleTitle>
        <Pagination>
          <StartPage>1343</StartPage>
          <EndPage>1345</EndPage>
          <MedlinePgn>1343-1345</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jpc.15101</ELocationID>
        <Abstract>
          <AbstractText>Kawasaki disease (KD) is an important cause of childhood vasculitis and a common cause of acquired heart disease in children world-wide. The emergence of Paediatric Multisystem Inflammatory Syndrome-Temporally Associated with SARS-CoV-2, a KD-like hyperinflammatory syndrome and the recent death of Dr Tomisaku Kawasaki make this a timely review. Although KD was described by Dr Kawasaki over 50 years ago, there is still no specific diagnostic test and the aetiology remains elusive. This article summarises the latest evidence, highlights important myths and misconceptions and discusses some of the mysteries that surround this disease.</AbstractText>
          <CopyrightInformation>© 2020 Paediatrics and Child Health Division (The Royal Australasian College of Physicians).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Butters</LastName>
            <ForeName>Coen</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0001-6499-337X</Identifier>
            <AffiliationInfo>
              <Affiliation>Infectious Diseases Unit, The Royal Children's Hospital, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Curtis</LastName>
            <ForeName>Nigel</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Infectious Diseases Unit, The Royal Children's Hospital, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Infection and Immunity Theme, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burgner</LastName>
            <ForeName>David P</ForeName>
            <Initials>DP</Initials>
            <Identifier Source="ORCID">0000-0002-8304-4302</Identifier>
            <AffiliationInfo>
              <Affiliation>Infectious Diseases Unit, The Royal Children's Hospital, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Infection and Immunity Theme, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>08</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Australia</Country>
        <MedlineTA>J Paediatr Child Health</MedlineTA>
        <NlmUniqueID>9005421</NlmUniqueID>
        <ISSNLinking>1034-4810</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
          <QualifierName UI="Q000302" MajorTopicYN="Y">isolation &amp; purification</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009080" MajorTopicYN="Y">Mucocutaneous Lymph Node Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">COVID-19</Keyword>
        <Keyword MajorTopicYN="Y">Kawasaki disease</Keyword>
        <Keyword MajorTopicYN="Y">general paediatrics</Keyword>
        <Keyword MajorTopicYN="Y">infectious diseases</Keyword>
        <Keyword MajorTopicYN="Y">intravenous immunoglobulin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32770807</ArticleId>
        <ArticleId IdType="doi">10.1111/jpc.15101</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Kawasaki T. Infantile acute febrile mucocutaneous lymph node syndrome with specific desquamation of the fingers and toes. Clinical observation of 50 cases. Jpn J. Allerg. 1967; 16: 178-222 (in Japanese with English abstract).</Citation>
        </Reference>
        <Reference>
          <Citation>Schudel M. Tomisaku Kawasaki, doctor who identified inflammatory disease in children, dies at 95. The Washington Post 2020; 14 Jun 14. Available from: https://www.washingtonpost.com/local/obituaries/tomisaku-kawasaki-doctor-who-identified-inflammatory-disease-in-children-dies-at-95/2020/06/13/35510b8e-ada0-11ea-9063-e69bd6520940_story.html [accessed 15 June 2020].</Citation>
        </Reference>
        <Reference>
          <Citation>McCrindle BW, Rowley AH, Newburger JW et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Circulation 2017; 135: e927.</Citation>
        </Reference>
        <Reference>
          <Citation>Ae R, Makino N, Kosami K, Kuwabara M, Matsubara Y, Nakamura Y. Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: The nationwide survey in Japan, 2017-2018. J. Pediatr. 2020. https://doi.org/10.1016/j.jpeds.2020.05.034.</Citation>
        </Reference>
        <Reference>
          <Citation>Saundankar J, Yim D, Itotoh B et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics 2014; 133: e1009-14.</Citation>
        </Reference>
        <Reference>
          <Citation>Rodó X, Ballester J, Cayan D et al. Association of Kawasaki disease with tropospheric wind patterns. Sci. Rep. 2011; 1: 152.</Citation>
        </Reference>
        <Reference>
          <Citation>Dietz SM, van Stijn D, Burgner D et al. Dissecting Kawasaki disease: A state-of-the-art review. Eur. J. Pediatr. 2017; 176: 995-1009.</Citation>
        </Reference>
        <Reference>
          <Citation>Whittaker E, Bamford A, Kenny J et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; e2010369. https://doi.org/10.1001/jama.2020.10369.</Citation>
        </Reference>
        <Reference>
          <Citation>Turnier JL, Anderson MS, Heizer HR, Jone PN, Glodé PM, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatrics 2015; 136: e609-14.</Citation>
        </Reference>
        <Reference>
          <Citation>Kanegaye JT, Wilder MS, Molkara D et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123: e783-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Phuong LK, Curtis N, Gowdie P, Akikusa P, Burgner D. Treatment options for resistant Kawasaki disease. Pediatr. Drugs 2018; 20: 59-80.</Citation>
        </Reference>
        <Reference>
          <Citation>Ho LGY, Curtis N. What dose of aspirin should be used in the initial treatment of Kawasaki disease? Arch. Dis. Child. 2017; 102: 1180-2.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
